Targeted Oral Fixed-Dose Combination of Amphotericin B-Miltefosine for Visceral Leishmaniasis
Molecular Pharmaceutics · 2025
DOI: 10.1021/acs.molpharmaceut.4c01133 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Raquel Fernández-García und 11 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Farmacia Galénica y Tecnología Alimentaria, Facultad de Farmacia, Universidad Complutense de Madrid. Plaza de Ramón y Cajal, s/n, 280…. Hauptthemen laut MEDLINE: Amphotericin B, Leishmaniasis, Visceral, Phosphorylcholine, Antiprotozoal Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerio de Ciencia, Innovaci?n y Universidades, Agencia Estatal de Investigaci?n, Science Foundation Ireland.
Abstract (Originalsprache)
The incidence of visceral leishmaniasis (VL) remains a significant health threat in endemic countries. Fixed-dose combination (FDC) of amphotericin B (AmB) and miltefosine (MLT) is a promising strategy for treating VL, but the parenteral administration of AmB leads to severe side effects, limiting its use in clinical practice. Here, we developed novel FDC granules combining AmB in the core with a MLT coating using wet granulation followed by the fluidized bed technology. The granules maintained the crystalline structure of AmB throughout manufacturing, achieving an AmB loading of ∼20%. The MLT coating layer effectively sustained AmB release from 3 to 24 h following Korsmeyer-Peppas kinetics. The formulation demonstrated remarkable stability, maintaining >90% drug content for over a year at both 4 °C and room temperature under desiccated conditions. In vivo efficacy studies in Leishmania infantum-infected hamsters showed 65-80% reduction in parasite burden in spleen and liver, respectively, suggesting potential as an oral alternative to current VL treatments. Uncoated and coated granules demonstrated comparable performance in key aspects, including in vivo efficacy and long-term stability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departamento de Farmacia Galénica y Tecnología Alimentaria, Facultad de Farmacia, Universidad Complutense de Madrid. Plaza de Ramón y Cajal, s/n, 28040 Madrid, Spain.
- School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin 2, Ireland.
- Institute of Biosciences, São Paulo State University (UNESP), Praça Infante Dom Henrique, s/n, São Vicente, São Paulo 11330-900, Brazil.
- Institute for Advanced Studies of Ocean (IEAMAR), São Paulo State University (UNESP), Rua João Francisco Bensdorp, 1178. São Vicente, São Paulo 11350-011, Brazil.
- Laboratório de Patologia das Moléstias Infecciosas (LIM/50), Faculdade de Medicina, Universidade de São Paulo, Avenida Dr. Arnaldo, 455, Cerqueira César, São Paulo 01246903, Brazil.
- Departamento de Farmacia, Facultad de Ciencias de la Salud, Universidad Cardenal Herrera-CEU, Carrer Santiago Ramón y Cajal, s/n., 46113 Valencia, Spain.
ORCID-Profile: Anne Marie Healy, Dolores R Serrano
Förderung
- Ministerio de Ciencia, Innovaci?n y Universidades
- Agencia Estatal de Investigaci?n
- Science Foundation Ireland
- Universidad Complutense de Madrid
- Conselho Nacional de Desenvolvimento Cient?fico e Tecnol?gico
- Funda??o de Amparo ? Pesquisa do Estado de S?o Paulo
- Banco de Santander
Zitieren
APA
Fernández-García, R., Walsh, D., O'Connell, P., Passero, L. F. D., de Jesus, J. A., Laurenti, M. D., Dea-Ayuela, M. A., Ballesteros, M. P., Lalatsa, A., Bolás-Fernández, F., Healy, A. M., & Serrano, D. R. (2025). Targeted Oral Fixed-Dose Combination of Amphotericin B-Miltefosine for Visceral Leishmaniasis. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c01133
Vancouver
Fernández-García R, Walsh D, O'Connell P, Passero LFD, de Jesus JA, Laurenti MD, et al. Targeted Oral Fixed-Dose Combination of Amphotericin B-Miltefosine for Visceral Leishmaniasis. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.4c01133
BibTeX
@article{FernndezGarca2025,
author = {Fernández-García, Raquel and Walsh, David and O'Connell, Peter and Passero, Luiz Felipe D and de Jesus, Jéssica A and Laurenti, Marcia Dalastra and Dea-Ayuela, María Auxiliadora and Ballesteros, M Paloma and Lalatsa, Aikaterini and Bolás-Fernández, Francisco and Healy, Anne Marie and Serrano, Dolores R},
title = {Targeted Oral Fixed-Dose Combination of Amphotericin B-Miltefosine for Visceral Leishmaniasis},
journal = {Molecular Pharmaceutics},
year = {2025},
doi = {10.1021/acs.molpharmaceut.4c01133}
}
EUVIMED